Insider · CIK 0001731164
Alison Cecily Finger
Files at ADMA (ADMA BIOLOGICS, INC.). First filing -, latest -.
Alison Cecily Finger files SEC Form 4 as director at ADMA (ADMA BIOLOGICS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Alison Cecily Finger has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | ADMA ADMA BIOLOGICS, INC. | AGrant or award Common Stock | +10,690 | $0.00 | $0 | 45,619 | Feb 11, 2026 |
| Feb 9, 2026 | ADMA ADMA BIOLOGICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +17,730 | $0.00 | $0 | 17,730 | Feb 11, 2026 |
| Feb 19, 2025 | ADMA ADMA BIOLOGICS, INC. | AGrant or award Common Stock | +10,889 | $0.00 | $0 | 34,929 | Feb 21, 2025 |
| Feb 19, 2025 | ADMA ADMA BIOLOGICS, INC. | AGrant or award Stock Option (right to buy)derivative | +16,279 | $0.00 | $0 | 16,279 | Feb 21, 2025 |
Questions about Alison Cecily Finger
Answered from the filings on this page, as of the latest one.
Is Alison Cecily Finger buying or selling?
Alison Cecily Finger has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Alison Cecily Finger's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Alison Cecily Finger has 0.
Where does Alison Cecily Finger file Form 4?
Alison Cecily Finger has filed Form 4 at ADMA (ADMA BIOLOGICS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.